Arrowhead Investors Ask 9th Circ. To Restore Drug Trial Suit
A proposed class of Arrowhead Research Corp. investors has urged the Ninth Circuit to revive claims that the company overstated hepatitis B vaccine trial results, saying scientific papers containing the truth...To view the full article, register now.
Already a subscriber? Click here to view full article